U.S. markets close in 2 hours 5 minutes
  • S&P 500

    4,172.22
    +59.72 (+1.45%)
     
  • Dow 30

    34,379.54
    +358.09 (+1.05%)
     
  • Nasdaq

    13,399.85
    +274.87 (+2.09%)
     
  • Russell 2000

    2,213.44
    +42.49 (+1.96%)
     
  • Crude Oil

    65.23
    +1.41 (+2.21%)
     
  • Gold

    1,838.20
    +14.20 (+0.78%)
     
  • Silver

    27.38
    +0.32 (+1.19%)
     
  • EUR/USD

    1.2142
    +0.0057 (+0.47%)
     
  • 10-Yr Bond

    1.6440
    -0.0240 (-1.44%)
     
  • GBP/USD

    1.4088
    +0.0037 (+0.26%)
     
  • USD/JPY

    109.4210
    -0.0130 (-0.01%)
     
  • BTC-USD

    50,664.01
    +2,460.91 (+5.11%)
     
  • CMC Crypto 200

    1,419.12
    +60.56 (+4.46%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET, being held in Boston.

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the European Union. Coherus is advancing late-stage clinical products CHS-1420, Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar and Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization, and early-stage clinical products, CHS-2020, Eylea® (aflibercept) biosimilar, and CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.

Contact

David S. Arrington
VP, Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196